SIM2 Agonist Therapy Guided by Genetic Testing for Parkinson's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease are ineffective and the exact cause is unknown, with existing therapies only alleviating symptoms, and there is no cure for the progressive neurodegenerative disorder.
Innovation Solution
Administering a SIM2 agonist to subjects with SIM2 variant nucleic acid molecules, particularly those that are heterozygous or homozygous for SIM2 variants, to inhibit or prevent the development of Parkinson's disease, and using genetic analysis to determine the presence of SIM2 variants to tailor treatment dosages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Parkinson's disease therapies are administered, then symptoms are alleviated, but the disease progression is not halted and no cure is achieved
Solution Approach 1:
The patent performs genetic testing for SIM2 variants before initiating treatment to identify patients who will respond to SIM2 agonist therapy. This preliminary action enables targeted treatment selection, ensuring that patients receiving SIM2 agonists are those with the specific genetic variant, thereby improving treatment reliability while avoiding unnecessary treatments in non-responders.
Solution Approach 2:
The patent changes the treatment parameter from general symptom management to targeted molecular intervention by administering SIM2 agonists specifically to patients with SIM2 variants. This parameter change transforms the approach from non-specific symptomatic relief to precise disease-modifying therapy, addressing both symptom alleviation and disease progression control.
2Measurement precision
If SIM2 agonist treatment is targeted to patients with SIM2 variants, then treatment precision is improved, but additional genetic testing is required
Solution Approach 1:
The patent replaces complex clinical assessment and trial-and-error treatment selection with a straightforward genetic test for SIM2 variants. This substitution uses molecular biology methods to directly identify the relevant biological marker, simplifying the diagnostic process while dramatically improving patient selection accuracy compared to traditional phenomenological approaches.
3Ease of operation
If standard Parkinson's disease treatments are administered to all patients, then treatment simplicity is maintained, but treatment effectiveness varies across different patient genotypes
Solution Approach 1:
The patent applies the principle of local quality by tailoring the treatment approach to the specific genetic characteristics of each patient. Instead of uniform treatment for all Parkinson's patients, the patent identifies SIM2 variant-positive patients and administers SIM2 agonists specifically to this subgroup, ensuring that each patient receives the locally appropriate treatment for their genetic profile, thereby improving response consistency.
Data Source
AI summary
The present disclosure generally relates to the treatment of subjects having Parkinson's disease or at risk of developing Parkinson's disease by administering a SIM BHLH Transcription Factor 2 (SIM2) agonist to the subject.